Life-threatening hyperkalemia associated with axitinib treatment in patients with recurrent renal carcinoma

Shigeo Godo, Yoshitaro Yoshida, Naoki Kawamorita, Koji Mitsuzuka, Yu Kawazoe, Motoo Fujita, Daisuke Kudo, Ryosuke Nomura, Hiroaki Shimokawa, Shigeki Kushimoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Axitinib has emerged as a promising antineoplastic agent for the treatment of advanced renal cell carcinoma. Although the administration of axitinib was well-tolerated in clinical trials, the real-world safety and tolerability remain unverified. We herein report a patient with metastatic renal cell carcinoma who suddenly developed life-threatening hyperkalemia following the initiation of axitinib treatment. Although hyperkalemia has been reported with an incidence of <10%, acute severe hyperkalemia may be a considerably critical adverse event of axitinib therapy, especially in patients with risk factors for hyperkalemia. An abundance of caution for unusual and unpredictable toxicities is warranted when using axitinib.

Original languageEnglish
Pages (from-to)2895-2900
Number of pages6
JournalInternal Medicine
Volume57
Issue number19
DOIs
Publication statusPublished - 2018 Jan 1

Keywords

  • Adverse event
  • Axitinib
  • Hyperkalemia
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Life-threatening hyperkalemia associated with axitinib treatment in patients with recurrent renal carcinoma'. Together they form a unique fingerprint.

  • Cite this